CP-506 is under clinical development by Convert Pharmaceuticals and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CP-506’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CP-506 overview
CP-506 is under development for the treatment of solid tumors including ovarian cancer, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer and head and neck cancer and small cell lung cancer. The drug candidate is a nitroaromatic analogue which acts by targeting kinase. It acts as a DNA alkylating agent. It is administered through intravenous route.
It was also under development for the treatment of non small cell lung cancer, colon cancer, cervical cancer.
Convert Pharmaceuticals overview
Convert Pharmaceuticals is a preclinical stage drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit. The company is headquartered in Liège, Liege, Belgium.
For a complete picture of CP-506’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
